Overview

Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer

Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this Phase 1 study is to identify the recommended dose of capiri and of sunitinib for combination therapy subsequent phase II trials.
Phase:
Phase 1
Details
Lead Sponsor:
Radboud University
Treatments:
Capecitabine
Irinotecan
Sunitinib